Ken Griffin Y M Abs Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 5,600 shares of YMAB stock, worth $28,504. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,600

Previous 20,300 72.41%

Holding current value

$28,504

Previous $266,000 83.83%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$7.76 - $15.69 $408,432 - $825,811	-52,633 Reduced 19.17%	221,914 $1.74 Million
Q3 2024 Nov 14, 2024	BUY	$9.95 - $15.39 $127,389 - $197,038	12,803 Added 4.89%	274,547 $3.6 Million
Q2 2024 Aug 14, 2024	BUY	$11.6 - $17.25 $1.66 Million - $2.47 Million	143,443 Added 121.25%	261,744 $3.16 Million
Q1 2024 May 15, 2024	SELL	$6.57 - $18.69 $126,137 - $358,829	-19,199 Reduced 13.96%	118,301 $1.92 Million
Q4 2023 Feb 14, 2024	SELL	$4.88 - $7.42 $1.35 Million - $2.05 Million	-276,807 Reduced 66.81%	137,500 $937,000
Q3 2023 Nov 14, 2023	BUY	$4.86 - $7.23 $1.86 Million - $2.77 Million	382,794 Added 1214.72%	414,307 $2.26 Million
Q2 2023 Aug 14, 2023	SELL	$5.68 - $10.34 $1.56 Million - $2.84 Million	-274,197 Reduced 89.69%	31,513 $213,000
Q1 2023 May 15, 2023	SELL	$2.83 - $5.11 $1.85 Million - $3.35 Million	-654,711 Reduced 68.17%	305,710 $1.53 Million
Q4 2022 Feb 14, 2023	BUY	$3.0 - $15.17 $2.61 Million - $13.2 Million	869,961 Added 961.71%	960,421 $4.69 Million
Q3 2022 Nov 14, 2022	BUY	$13.96 - $19.67 $1.26 Million - $1.78 Million	90,460 New	90,460 $1.3 Million
Q1 2022 May 16, 2022	SELL	$6.55 - $17.42 $646,950 - $1.72 Million	-98,771 Reduced 78.58%	26,927 $320,000
Q4 2021 Feb 14, 2022	BUY	$15.51 - $29.31 $328,548 - $620,873	21,183 Added 20.27%	125,698 $2.04 Million
Q3 2021 Nov 15, 2021	SELL	$27.47 - $37.31 $1.94 Million - $2.64 Million	-70,670 Reduced 40.34%	104,515 $2.98 Million
Q2 2021 Aug 16, 2021	BUY	$25.45 - $37.64 $2.13 Million - $3.15 Million	83,790 Added 91.68%	175,185 $5.92 Million
Q1 2021 May 17, 2021	SELL	$29.16 - $51.96 $701,997 - $1.25 Million	-24,074 Reduced 20.85%	91,395 $2.76 Million
Q4 2020 Feb 16, 2021	BUY	$37.86 - $54.26 $4.02 Million - $5.77 Million	106,301 Added 1159.48%	115,469 $5.72 Million
Q3 2020 Nov 16, 2020	SELL	$35.13 - $43.62 $134,618 - $167,151	-3,832 Reduced 29.48%	9,168 $352,000
Q2 2020 Aug 14, 2020	SELL	$23.66 - $49.53 $589,441 - $1.23 Million	-24,913 Reduced 65.71%	13,000 $561,000
Q1 2020 May 15, 2020	SELL	$14.39 - $35.8 $466,451 - $1.16 Million	-32,415 Reduced 46.09%	37,913 $990,000
Q4 2019 Feb 14, 2020	BUY	$23.81 - $33.78 $1.67 Million - $2.38 Million	70,328 New	70,328 $2.2 Million

Others Institutions Holding YMAB

# of Institutions

113

Shares Held

26.9M

Call Options Held

5.6K

Put Options Held

900

View Full List

About Y-mAbs Therapeutics, Inc.

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $223M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

More about YMAB

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account